Pursuant to legislation passed by the North Carolina General Assembly [Session Law 2023-134, Sections 9E.17(a)-(d)], the meeting cadence for the NC Medicaid Preferred Drug List (PDL) Review Panel meetings has increased from twice yearly to quarterly. This update supports efforts by NCDHHS to focus on and strengthen behavioral healthcare for North Carolinians.
This change will expedite the determination of non-preferred or preferred status for FDA-approved, new-to-market, rebate-eligible medications for the treatment of the behavioral health conditions listed in the legislative bill.
Please note that due to this act by the North Carolina General Assembly, the 45-day public comment period for the proposed PDL changes transitioned to a 30-day comment period beginning in 2024.
For additional information on the NC Medicaid PDL, including review panel guidelines and meeting information, visit the Preferred Drug List Review Panel webpage. For the most recent revision of the PDL as well as archived copies, visit the Preferred Drug List webpage.
Contact
NC Medicaid Contact Center, 888-245-0179